|
|
Post by Clement on Mar 31, 2020 10:28:44 GMT -5
|
|
|
|
Post by brotherm1 on Apr 2, 2020 7:27:35 GMT -5
On top of this, Cantor Fitzgerald’s Brandon Folkes notes, “MNKD continues to have excess manufacturing capacity which it can leverage to assist other companies in meeting any increased demand due to the outbreak.” MNKD has excess manufacturing capacity it can use for other than Afrezza and treprostinil? Where? Is it possible to have other drugs produced on the two production lines while still producing Afrezza and treprostinil? |
|
|
|
Post by sportsrancho on Apr 2, 2020 7:30:17 GMT -5
On top of this, Cantor Fitzgerald’s Brandon Folkes notes, “MNKD continues to have excess manufacturing capacity which it can leverage to assist other companies in meeting any increased demand due to the outbreak.” MNKD has excess manufacturing capacity it can use for other than Afrezza and treprostinil? Where? Is it possible to have other drugs produced on the two production lines while still producing Afrezza and treprostinil? That’s what Spencer‘s been talking about on Stocktwits. |
|
|
|
Post by boca1girl on Apr 2, 2020 9:01:01 GMT -5
On top of this, Cantor Fitzgerald’s Brandon Folkes notes, “MNKD continues to have excess manufacturing capacity which it can leverage to assist other companies in meeting any increased demand due to the outbreak.” MNKD has excess manufacturing capacity it can use for other than Afrezza and treprostinil? Where? Is it possible to have other drugs produced on the two production lines while still producing Afrezza and treprostinil? They have empty floor space in their manufacturing plant. |
|
|
|
Post by mnholdem on Apr 2, 2020 11:29:31 GMT -5
On top of this, Cantor Fitzgerald’s Brandon Folkes notes, “MNKD continues to have excess manufacturing capacity which it can leverage to assist other companies in meeting any increased demand due to the outbreak.” MNKD has excess manufacturing capacity it can use for other than Afrezza and treprostinil? Where? Is it possible to have other drugs produced on the two production lines while still producing Afrezza and treprostinil? Unless memory fails, former CEO/CFO Matthew Pfeffer had built out 3 finish-fill lines, not 2 lines, with the final line having a considerably higher capacity and/or production rate than the first line, which was completed many years ago at the Danbury CT facility.  |
|
|
|
Post by Clement on Apr 2, 2020 11:37:05 GMT -5
July 11, 2019 investors.mannkindcorp.com/news-releases/news-release-details/mannkind-expands-commercial-scale-manufacturing-capabilitiesMannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules WESTLAKE VILLAGE, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation(Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced that it has completed construction of a new high-potency manufacturing suite in its Danbury Connecticut facility. This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships. The new suite will house bulk powder formulation and fill/pack operations for high-potency powders and adds to MannKind's extensive commercial manufacturing capability, which includes inhalation devices, large-scale compounding, particle formation, tangential flow filtration, cryogranulation, and high capacity (300 kg/day) lyophilization. |
|
|
|
Post by mannmade on Apr 2, 2020 14:53:18 GMT -5
you are correct holdem
|
|
|
|
Post by brotherm1 on Apr 2, 2020 14:59:12 GMT -5
This latter expansion for Trep is for Trep as noted above, and MC said they will be expanding that one for UTHR. Perhaps they are working on it now in preparation for large scale production of Trep when the time comes (he last said something like they have plenty of time to do it as it only takes 4-5 months). Perhaps they could also use this expansion when complete until time for mass Trep production in a couple of years?
|
|
|
|
Post by brotherm1 on Apr 2, 2020 15:00:31 GMT -5
On top of this, Cantor Fitzgerald’s Brandon Folkes notes, “MNKD continues to have excess manufacturing capacity which it can leverage to assist other companies in meeting any increased demand due to the outbreak.” MNKD has excess manufacturing capacity it can use for other than Afrezza and treprostinil? Where? Is it possible to have other drugs produced on the two production lines while still producing Afrezza and treprostinil? That’s what Spencer‘s been talking about on Stocktwits. What him said? |
|
|
|
Post by sportsrancho on Apr 2, 2020 15:02:28 GMT -5
That’s what Spencer‘s been talking about on Stocktwits. What him said? You have to go to google and look at up. I’ll try and do it later when I get time. That’s if he has you blocked if he doesn’t have you blocked you should be able to see it. |
|
|
|
Post by wyattdog on Apr 2, 2020 15:09:16 GMT -5
spencerosborne
3/25/20, 07:49 PM
$MNKD a few weeks back I made the point that MNKD has excess space at its CT manufacturing facility and that the company has more leverage now than it will ever have to take on toll manufacturing. Every day it is getting more obvious that the US is too reliant on China for pharmaceuticals. Hopefully the company is working on this. We shall see.
|
|
|
|
Post by wyattdog on Apr 2, 2020 15:10:50 GMT -5
spencerosborne
3/26/20, 08:00 AM
@johnkastanes the point is to get these, or some, capabilities stateside. Mnkd has untapped tax free space which can be used for toll manufacturing. There us s hunger to do this now....even if imperfect....there is value to any big pharma to say, " we make XYZ drug in the US."
|
|
|
|
Post by brotherm1 on Apr 2, 2020 15:11:53 GMT -5
Thanks. I take back almost everything I said about him 😎
|
|
|
|
Post by sportsrancho on Apr 2, 2020 15:14:43 GMT -5
spencerosborne 3/26/20, 08:00 AM @johnkastanes the point is to get these, or some, capabilities stateside. Mnkd has untapped tax free space which can be used for toll manufacturing. There us s hunger to do this now....even if imperfect....there is value to any big pharma to say, " we make XYZ drug in the US." 👍🏻Thank you:-) |
|
